Treatment of Hepatitis C Completed Phase 2 Trials for Ledipasvir (DB09027)

IndicationStatusPhase
DBCOND0076480 (Treatment of Hepatitis C)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02480387Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infectionTreatment